Business Wire

Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Jaa

Incyte Corporation (Nasdaq:INCY) today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with pembrolizumab (KEYTRUDA®), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ USA (known as MSD outside the United States and Canada), will be highlighted in multiple presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Updated efficacy data at ASCO are from multiple tumor cohorts – metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), advanced urothelial bladder cancer (UC), and advanced renal cell carcinoma (RCC) – as well as a pooled safety analysis (Phase 2) of the total study population (across all tumor cohorts). Data will be highlighted in two oral presentations (SCCHN and UC) and two poster discussions (RCC and pooled safety).

“We are pleased to report additional data from multiple tumor-specific cohorts of our Phase 1/2 ECHO-202 trial, which continue to provide encouraging efficacy and safety data for this investigational treatment combination,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These and other data presented here in Chicago underscore the potential of this novel investigational immunotherapy combination in multiple advanced cancers, supporting the advancement of our clinical development program for epacadostat and pembrolizumab into multiple Phase 3 clinical trials.”

Efficacy Data from ECHO-202 (Abstract #6010, #4503, #4515)
Results of these tumor cohorts (as of February 27, 2017) include:

     

SCCHN
(Abstract #6010)

UC
(Abstract #4503)

RCC
(Abstract #4515)

Total
Subgroup
N (%)

 

Prior Lines of
Treatment
N (%)

Total
Subgroup
N (%)

 

Prior Lines of
Treatment
N (%)

Total
Subgroup
N (%)

 

Prior Lines of
Treatment
N (%)

Total 1-2   >3 Total 0-1   ≥2 Total 0-1   ≥2
13/38 12/31 1/7 14/40 12/32 2/8 10/30 9/19 1/11
(34) (39) (14) (35) (38) (25) (33) (47) (9)
ORR
3 CR 3 CR 1 PR 3 CR 3 CR 2 PR 1 CR 1 CR 1 PR
  10 PR 9 PR   11 PR 9 PR   9 PR 8 PR  
DCR 23/38 20/31 3/7 21/40 19/32 2/8 15/30 11/19 4/11
  (61) (65) (43) (53) (59) (25) (50) (58) (36)
10/13 responses ongoing 10/14 responses ongoing 7/10 responses ongoing
DoR Median range: 18.4+ (7.1 to Median range: 30.6+ (9.7 to 93.1+) Median range: 26.8+ (18.1+ to 53.1)
  90.3+) weeks weeks weeks
 

Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DoR), Complete Response (CR), Partial Response (PR)

Safety Data from ECHO-202 (Abstract #3012)

In addition to the efficacy data above, an updated pooled analysis evaluated 294 patients with advanced cancers in the ECHO-202 Phase 2 safety population. Treatment-related adverse events (TRAEs) occurred in 67 percent (n=197/294) of patients. The most common TRAEs included fatigue (29%), rash (17%), nausea (11%), and pruritus (10%). Grade ≥3 TRAEs occurred in 18 percent (n=52/294) of patients, the most common of which were increased lipase (asymptomatic) (4%) and rash (3%). TRAEs led to discontinuation of treatment in four percent of study patients. The safety profile of epacadostat plus pembrolizumab was generally consistent with previously reported ECHO-202 Phase 1 data and with the safety profile of KEYTRUDA monotherapy.

“The combination of pembrolizumab and epacadostat as a treatment for multiple advanced solid tumors has shown promise in our preliminary Phase 1/2 clinical trials,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “We welcome the opportunity to collaborate with Incyte and we look forward to progressing this combination in pivotal trials.”

About ECHO-202 (KEYNOTE-037)

The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 inhibitor, in combination with pembrolizumab (KEYTRUDA). Patients previously treated with anti-PD-1 or anti-CTLA-4 therapies were excluded from this trial. Enrollment is complete for the Phase 1 dose escalation (epacadostat 25, 50, 100 mg BID + pembrolizumab 2 mg/kg IV Q3W and epacadostat 300 mg BID + pembrolizumab 200 mg IV Q3W) and Phase 1 dose expansion (epacadostat 50, 100, and 300 mg BID + pembrolizumab 200 mg IV Q3W) portions of the trial. For more information about ECHO-202, visit https://clinicaltrials.gov/ct2/show/NCT02178722.

About ECHO

The ECHO clinical trial program was established to investigate the efficacy and safety of epacadostat as a core component of combination therapy in oncology. Ongoing Phase 1 and Phase 2 studies evaluating epacadostat in combination with PD-1 and PD-L1 inhibitors collectively plan to enroll over 900 patients in a broad range of solid tumor types as well as hematological malignancies. ECHO-301 (NCT02752074), a Phase 3 randomized, double-blind, placebo-controlled study investigating pembrolizumab (KEYTRUDA) in combination with epacadostat or placebo for the treatment of patients with unresectable or metastatic melanoma, is also underway. For more information about the ECHO clinical trial program, visit www.ECHOClinicalTrials.com.

About Epacadostat (INCB024360)

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive enzyme that modulates the anti-tumor immune response by promoting regulatory T cell generation and blocking effector T cell activation, thereby facilitating tumor growth by allowing cancer cells to avoid immune surveillance. Epacadostat is an investigational, highly potent and selective oral inhibitor of the IDO1 enzyme that regulates the tumor immune microenvironment, thereby restoring effective anti-tumor immune responses. In single-arm studies, the combination of epacadostat and immune checkpoint inhibitors has shown proof-of-concept in patients with unresectable or metastatic melanoma. In these studies, epacadostat combined with the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor pembrolizumab (KEYTRUDA) improved response rates compared with studies of the immune checkpoint inhibitors alone.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward-Looking Statement of Incyte Corporation

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation and discussion of data regarding the Company’s ECHO-202 study and the planned pivotal trials of epacadostat in combination with pembrolizumab, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2017. Incyte disclaims any intent or obligation to update these forward-looking statements.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA.

Contact information

Incyte
Media
Catalina Loveman
+1 302-498-6171
or
Investors
Michael Booth, DPhil
+1 302-498-5914

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GSMA: Multiple Mobile Operators Launch Live Commercial Low Power Wide Area Networks in Licensed Spectrum Worldwide21.2.2018 12:00Tiedote

The GSMA today announced that momentum behind Mobile IoT, or licensed Low Power Wide Area (LPWA), networks continues to grow on a global basis. To date, 23 mobile operators have commercially launched 41 Mobile IoT networks worldwide across both NB-IoT1 and LTE-M2. This growth is supported by 34 IoT Labs and an expanding community of over 800 organisations in the GSMA’s Mobile IoT Innovators Community. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections. “2018 is the year that Mobile IoT networks will scale. We have seen huge growth in the availability of commercial networks in licensed spectrum and anticipate seeing many more launches this year. This is underpinned by an expanding community of organisations developing innovative new solutions and a number of IoT Labs helping companies to test out new products and services,” said Alex Sinclair, Chief Technology Officer, GSMA. “Mobile IoT ne

Clientron to Present Its POS Innovation at EuroCIS 201821.2.2018 12:00Tiedote

Clientron Corp., a global leading provider of POS, thin client, and embedded systems, will display its latest POS solutions for the retail market at the world’s leading retail show, EuroCIS 2018, from February 27 to March 1, 2018 in Dusseldorf, Germany. At its Booth (Hall 10, Booth E73), Clientron will introduce its innovative POS terminals and various built-in POS peripherals available on the market today in order to meet the demands of omnicommerce experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005007/en/ Clientron to present its POS innovation at EuroCIS 2018 At the event, Clientron's displays will include: the innovative PST650 all-in-one POS terminal with a built-in high speed thermal printer and a small, lightweight form factor for counter space savings; the most affordable POS terminal, PT2000, in a fanless design with long life span support to both entry and mainstream POS market segments; and the ne

Fake Medicines Continue to Threaten Consumers – EU Member States have an Obligation to Act21.2.2018 11:12Tiedote

According to The Alliance for Safe Online Pharmacy in the EU (ASOP EU), the illegal manufacturing and distribution of fake medicines is an enormous and growing public health risk with an untold cost to lives. "Vast profits are made by organized criminal gangs who often use the proceeds to support other criminal activities. The Internet provides the ideal channel to buy illegally distributed fake medicines. Price, convenience and secrecy have driven consumer demand, creating the perfect environment for over 35,000 illegally operating websites." Under article 85d of the Falsified Medicines Directive, each EU Member State is obliged to raise awareness about the risks of buying medicines online. To better understand how countries are meeting these obligations to educate and protect consumers, the European Union’s Alliance for Safe Online Pharmacy (ASOP EU) and the European Alliance for Access to Safe Medicines (EAASM), has convened a series of discussions with many Member States. Based on

Triton Digital Integrates Platform 161 with a2x® to Provide Marketers and Buyers with Access to Premium Digital Audio Advertising Inventory21.2.2018 11:00Tiedote

Triton Digital®, the global technology and services leader to the digital audio and podcast industry, announced today the integration of its audio advertising marketplace, a2x®, with Platform 161, a leading DSP for advertisers, agencies and publishers. The integration provides Platform 161’s advertisers with the ability to add online audio from top-tier broadcasters and streaming music services to their programmatic, omnichannel buys through both open auction and private marketplace (PMP) deals. “We are proud to partner with Triton Digital to provide our marketers with access to a wide range of digital audio inventory from music services, live streaming radio, podcasts, and more through the a2x programmatic audio marketplace,” said Marco Kloots, CEO at Platform 161. “The personal, highly-engaging nature of digital audio will undeniably enhance our marketers omnichannel buys, enabling them to both scale their buys and connect with their target audience in a native, immersive manner acro

Posiflex Showcases Stylish New Line of Touch Screen Terminals and Self-Service & Interactive Kiosks at EuroCIS 201821.2.2018 11:00Tiedote

Posiflex Technology, Inc. unveils an entirely new line of dynamic touch screen terminals that embodies a new era for Posiflex and point-of-sale hardware – the RT Series. With an elegant housing and a strikingly thin profile, the RT Series brings a modern aesthetic to the counter and makes a retail business look even more attractive. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005002/en/ Make Your Business Look More Attractive with Posiflex RT Series (Photo: Business Wire) Available in 15” (4:3) screen or 15.6” (16:9) widescreen, the RT Series provides multiple CPU selection from Intel Celeron all the way to Core i5 CPU to fit each unique need. The patented fanless technology allows the unit to run silently and perform in harsh environments that involves dust and liquid spills. “POS terminal is no longer just a cold and hard business tool; it has evolved to be an extension of the brand offering a more dynamic in-store

Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies21.2.2018 10:00Tiedote

Regulatory News: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients. Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “This agreement brings together Ipsen’s deep expertise in drug development and commercialization with Ar

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme